Literature DB >> 17617865

Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients.

D Lilleri1, P Zelini, C Fornara, G Comolli, G Gerna.   

Abstract

CD4(+) and CD8(+) T cells specific for human cytomegalovirus (HCMV) and two immunodominant HCMV antigens (pp65 and IE-1) were monitored in 20 solid organ transplant recipients undergoing primary (n = 4) or reactivated (n = 16) HCMV infection during the first year after transplantation by using as a stimulator either HCMV-infected autologous dendritic cells (DCs) or pp65- or IE-1 peptide mixtures. Turnaround times for test performance were 7 days for infected DCs and 24 h for peptides. Using infected DCs, HCMV-specific T-cell restoration occurred in all patients for CD8(+) and in 18/20 (90%) for CD4(+) T-cell subpopulations, resulting in virus clearance from blood. Using peptide mixtures, T-cell responses were less frequently detected. In detail, 14 (70%) patients showed pp65-specific CD8(+) T cells and 10 (50%) patients IE-1-specific CD8(+) T cells, whereas pp65-specific CD4(+) T cells were detected in 14 (70%) patients, and IE-1-specific CD4(+) T cells in three (15%) patients only. Protection from HCMV infection was associated with the presence of a HCMV-specific T-cell response directed against multiple viral proteins, but not against pp65 or IE-1 only. In conclusion, the use of pp65 and IE-1 peptide mixtures for rapid monitoring of HCMV-specific T-cell responses in solid organ transplant recipients underestimates the actual T-cell immune response against HCMV.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17617865     DOI: 10.1111/j.1600-6143.2007.01890.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  12 in total

1.  Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.

Authors:  Corinna La Rosa; Ajit P Limaye; Aparna Krishnan; Gideon Blumstein; Jeff Longmate; Don J Diamond
Journal:  Transpl Int       Date:  2011-06-14       Impact factor: 3.782

2.  Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.

Authors:  L D Snyder; R Medinas; C Chan; S Sparks; W A Davis; S M Palmer; K J Weinhold
Journal:  Am J Transplant       Date:  2011-01-10       Impact factor: 8.086

3.  Expansion of human cytomegalovirus (HCMV) immediate-early 1-specific CD8+ T cells and control of HCMV replication after allogeneic stem cell transplantation.

Authors:  Karim Sacre; Stéphanie Nguyen; Claire Deback; Guislaine Carcelain; Jean-Paul Vernant; Véronique Leblond; Brigitte Autran; Nathalie Dhedin
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

Review 4.  Immunobiology of human cytomegalovirus: from bench to bedside.

Authors:  Tania Crough; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

5.  Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease.

Authors:  A Krishnan; W Zhou; S F Lacey; A P Limaye; D J Diamond; C La Rosa
Journal:  Transpl Infect Dis       Date:  2010-01-11       Impact factor: 2.228

6.  Precision mouse models with expanded tropism for human pathogens.

Authors:  Angela Wahl; Chandrav De; Maria Abad Fernandez; Erik M Lenarcic; Yinyan Xu; Adam S Cockrell; Rachel A Cleary; Claire E Johnson; Nathaniel J Schramm; Laura M Rank; Isabel G Newsome; Heather A Vincent; Wes Sanders; Christian R Aguilera-Sandoval; Allison Boone; William H Hildebrand; Paul A Dayton; Ralph S Baric; Raymond J Pickles; Miriam Braunstein; Nathaniel J Moorman; Nilu Goonetilleke; J Victor Garcia
Journal:  Nat Biotechnol       Date:  2019-08-26       Impact factor: 54.908

7.  An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients.

Authors:  Adrian Egli; Moacyr Silva; Daire O'Shea; Leticia E Wilson; Aliyah Baluch; Luiz F Lisboa; Luis G Hidalgo; Deepali Kumar; Atul Humar
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

8.  HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B recognized by CD4+ T-cell clones from chronically infected individuals.

Authors:  Claire Ventura; Hélène Bisceglia; Yves Girerd-Chambaz; Nicolas Burdin; Pascal Chaux
Journal:  J Clin Immunol       Date:  2012-07-15       Impact factor: 8.317

9.  Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.

Authors:  Adrian Egli; Isabelle Binet; Simone Binggeli; Clemens Jäger; Alexis Dumoulin; Stefan Schaub; Juerg Steiger; Urban Sester; Martina Sester; Hans H Hirsch
Journal:  J Transl Med       Date:  2008-06-09       Impact factor: 5.531

10.  Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients.

Authors:  Elisa Gabanti; Francesca Bruno; Daniele Lilleri; Chiara Fornara; Paola Zelini; Ilaria Cane; Clara Migotto; Eleonora Sarchi; Milena Furione; Giuseppe Gerna
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.